Skip to main content
Equibles
JBIO logo

JBIO · Jade Biosciences, Inc. · Metrics

Track JBIO — free

Use JBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research JBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.13 +0.27 (+1.82%) At close · Oct 21
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed Aug 10, 2026
Market Cap
$962.23M
Shares
63.60M
Volume · Oct 21 932.74K Avg daily vol (3M) 902.38K

JBIO metrics

55 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.13
Market cap
$962.23M

Price action

20 metrics
Price change (1W)
+10.7%
Price change (30D)
-11.2%
Price change (3M)
-27.6%
Price change (6M)
-35.4%
Price change (YTD)
-3.7%
Price change (1Y)
+48.6%
Trailing year
Price change (5Y)
—
52-week high
$26.85
52-week low
$8.95
Change from 52-week high
-44.7%
Change from 52-week low
+66.0%
Annualized volatility
72.3%
Annualized volatility (3M)
56.4%
Beta
1.3
RSI (14D)
47.2
Price vs SMA 50
-16.8%
Price vs SMA 200
-18.4%
Avg volume (3M)
902,030
Relative volume
1.0
Average dollar volume
$16.36M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
63.60M

Valuation

12 metrics
P / E (TTM)
1.8
Trailing earnings · reciprocal yield 56.8%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 46.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-16.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-10

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$164.74M
Net income (TTM)
−$153.24M
Trailing 12 months
Diluted EPS (TTM)
$8.44
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$6.74

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+114.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-34.8%
Return on assets
-32.5%
Debt / equity
—
Current ratio
14.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
14.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$461.20M
Latest balance sheet
Cash & equivalents
$107.25M
Total assets
$472.11M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$123.51M
Capital expenditures (TTM)
—
R&D (TTM)
$136.67M
SG&A (TTM)
—
Stock compensation (TTM)
$34.70M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
156
13F filer change QoQ
+34
Institutional ownership
114.8%
Conviction holders (share of 13F filers)
4.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+45.6%
Holder tenure
3.4
Price vs estimated holder cost
+24.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
10.1%

Short interest

3 metrics
Short interest
19.1%
Latest settlement · 11.3 days to cover
Days to cover
11.3d
Short-squeeze score
72 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1798749 CUSIP 008064206 13F (30d) 11 filings 11 filers Visit website Investor relations